ArticleFrontiers in oncology2024

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway.

Yasushi Iida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.